The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
COMy 2023 | Approaching a myeloma population becoming increasingly resistant to daratumumab
Gareth Morgan, MD, PhD, FRCP, FRCPath, NYU Langone Health, New York City, NY, discusses treatment options for patients with relapsed/refractory multiple myeloma (R/R MM) who have developed resistance to daratumumab. Prof. Morgan explains that daratumumab is the standard of care for newly presenting cases, but prolonged use can lead to resistance, and further highlights the role of belantamab mafodotin and bispecific antibodies as effective and mostly well tolerated treatment options for daratumumab-resistant patients. This interview took place at the 9th World Congress on Controversies in Multiple Myeloma (COMy) 2023, held in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
